DDInter1607 DDInter1837
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Toremifene
Ritonavir {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Toremifene
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clomifene
Clomifene {u} (Compound) resembles {v} (Compound) Toremifene
Ritonavir {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Ritonavir {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Hyperhidrosis {u} (Side Effect) is caused by {v} (Compound) Doxylamine
Doxylamine {u} (Compound) resembles {v} (Compound) Toremifene
Ritonavir {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Acute coronary syndrome {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Toremifene
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Toremifene
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Ritonavir (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Toremifene (Compound)
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may lead to a major life threatening interaction when taken with Toremifene
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clomifene (Compound) and Clomifene (Compound) resembles Toremifene (Compound)
Ritonavir (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Ritonavir (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Doxylamine (Compound) and Doxylamine (Compound) resembles Toremifene (Compound)
Ritonavir (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Toremifene
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Toremifene (Compound)